GHK-Cu and BPC-157 get lumped together as “healing peptides,” but they have very little in common. GHK-Cu is a tiny three-amino-acid peptide bound to copper. It occurs naturally in human blood, it is studied for collagen, skin remodelling and gene expression, and it is already sold in skincare. BPC-157 is a 15-amino-acid fragment first described from human gastric juice. It is studied mainly for blood-vessel growth, tendon, ligament and gut repair, and nearly all of that work comes from rats.
If your question is “GHK-Cu or BPC-157 for skin?”, the evidence clearly favours GHK-Cu. It has decades of topical cosmetic studies in people, although many are small, industry-linked or published only as abstracts. BPC-157 has no published human skin studies at all. For tendon and gut questions it is the other way round: BPC-157 has a large rodent literature, and GHK-Cu has little that is relevant.
In people, BPC-157 data are tiny: a two-person IV safety pilot, a 12-patient retrospective knee report and a 12-patient bladder pilot, none of them controlled. Neither compound is approved as a drug in Canada. That’s why both are discussed here as research compounds, not treatments.
GHK-Cu vs BPC-157 at a glance
Here is the whole comparison on one screen. The rest of the article explains each row and where the evidence comes from.
| GHK-Cu | BPC-157 | |
|---|---|---|
| What it is | Copper complex of the tripeptide glycyl-histidyl-lysine | Synthetic 15-amino-acid peptide (pentadecapeptide) |
| Natural source | Found in human plasma, saliva and urine | Described as a fragment of a protein in human gastric juice |
| First described | 1973, Loren Pickart (liver cell studies) | 1993, Predrag Sikiric’s group in Zagreb |
| Main research themes | Collagen and skin remodelling, wound repair, gene expression, hair follicle models | Angiogenesis, tendon and ligament healing, gut lesions, nitric-oxide system |
| Best human evidence | Topical cosmetic studies (creams), one wound-gel programme | Three small uncontrolled reports; no randomized trials published |
| Where you see it commercially | Skincare listed as “copper tripeptide-1” | Research-chemical market; not an approved drug anywhere |
| Colour | Blue (from copper) | White powder |
Where each peptide came from
GHK-Cu: a blood factor that made old liver tissue act younger
GHK’s story starts in 1973. Loren Pickart, working with liver tissue, found that something in the plasma of young people made liver tissue from older donors make proteins the way younger tissue does. That activity was traced to a tripeptide, later identified as glycyl-L-histidyl-L-lysine, or GHK, which binds copper very tightly.1
A detail that gets quoted a lot, and is worth getting right: Pickart’s group reports GHK plasma levels of about 200 ng/mL at age 20, falling to about 80 ng/mL by age 60.1 That decline is a big part of why GHK-Cu gets marketed as an “anti-aging” peptide. A falling blood level does not prove that topping it up reverses anything, though. That is a hypothesis, not a result.
BPC-157: a fragment from gastric juice
BPC stands for “body protection compound.” BPC-157 was first introduced by Sikiric and colleagues in 1993 as a pentadecapeptide derived from a protein found in human gastric juice.7 The compound researchers buy today is synthetic. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of about 1,419 daltons.7
One thing to know up front: most BPC-157 research has come from a small number of labs, and a large share from the same Zagreb group. A 2019 review in Cell and Tissue Research noted that “only a handful of research groups” have studied the peptide in depth.8 That doesn’t make the findings wrong. It does mean independent replication is thin. For a full background, see What is BPC-157?
Structure: 3 amino acids vs 15
The size difference matters more than it sounds.
- GHK-Cu is tiny. Three amino acids plus a copper(II) ion. Pickart’s review gives GHK a copper-binding affinity in the same range as albumin’s copper site,1 which is why GHK is described as a copper carrier as well as a signalling molecule. The copper is also why the powder and solutions are blue. We explain that in Why is GHK-Cu blue?
- BPC-157 is a mid-sized linear peptide. It has 15 residues, no metal and no unusual modifications. Sikiric’s group describes it as unusually stable, including in gastric juice.7 That claim is the backbone of the “oral BPC-157” debate, which we cover in a separate guide on oral vs injectable BPC-157.
Small size also helps explain why GHK-Cu has a topical (on-the-skin) research history and BPC-157 mostly does not. Even so, getting any peptide through intact skin is hard, and formulation matters a lot.
How they are thought to work
Both peptides have long lists of proposed mechanisms. Most come from cell culture and animal tissue, so treat them as “what the lab saw,” not “what happens in you.”
GHK-Cu: copper delivery and gene expression
- Extracellular matrix remodelling. In cell and animal studies, GHK-Cu is linked to collagen, elastin and glycosaminoglycan synthesis, and to regulation of the enzymes (MMPs and their inhibitors) that break down and rebuild tissue.1
- Gene-expression signatures. Pickart’s group mined the Broad Institute’s Connectivity Map, a database of gene-expression changes in cultured cells exposed to compounds. They report that GHK shifts the expression of at least 4,000 human genes.1 In one analysis, GHK reversed an emphysema-associated gene pattern linked to TGF-beta signalling.1 These are computational, cell-line results. They point to hypotheses, not clinical effects.
- Stem-cell and keratinocyte markers. In cultured basal keratinocytes, GHK-Cu increased integrin and p63 expression, markers associated with stem-like cells.1
BPC-157: blood vessels, cell migration and nitric oxide
- Angiogenesis via VEGFR2. Rat and cell studies report that BPC-157 activates the VEGFR2–Akt–Akt–eNOS pathway and increases vessel density.8
- Tendon fibroblast migration. In vitro, BPC-157 increased tendon fibroblast migration through the FAK–paxillin pathway and improved cell survival under oxidative stress. It did not directly increase proliferation.8 Another study reported upregulation of the growth hormone receptor in tendon fibroblasts.8
- Nitric-oxide system. Sikiric’s group repeatedly links BPC-157’s effects to the NO system.8
The angiogenesis angle is a double-edged sword. More blood supply sounds great for a torn tendon, but it is also why people ask whether BPC-157 could feed a tumour. That question is unresolved. We go through what is known in Does BPC-157 cause cancer?
Evidence quality by area
This is the table most comparison pages skip. We rate each area by the best type of evidence available, not by how exciting the results sound.
| Area | GHK-Cu: best evidence | BPC-157: best evidence |
|---|---|---|
| Skin (wrinkles, firmness) | Moderate-low. Several 12-week topical cream studies in women, mostly abstracts or industry-linked; one small randomized laser study with mixed results | None in humans. Rodent wound studies only |
| Hair | Low. Copper-peptide follicle data are in vitro, and the best-known study used AHK-Cu, not GHK-Cu | None. |
| Wounds and ulcers | Mixed. Positive early diabetic-ulcer trial; the larger pivotal programme failed against placebo | Preclinical. Many rat skin and fistula models |
| Tendon and ligament | Very little. | Preclinical, fairly consistent. Rat Achilles, MCL and muscle models; one uncontrolled human knee report |
| Gut | Very little. | Preclinical, large. Ulcer, colitis, fistula and short-bowel rat models; early ulcerative-colitis trials poorly reported |
| Systemic safety in humans | Topical use assessed as safe in cosmetics; no human data for injected GHK-Cu | Two-person IV pilot; overall human safety described as unknown |
Skin: GHK-Cu’s home turf
Pickart’s 2015 review summarizes the main human skin studies:1
- A one-month thigh-cream study with biopsies reported increased collagen in 70% of GHK-Cu users, versus 50% with a vitamin C cream and 40% with retinoic acid.
- A 12-week facial cream study in 71 women with photoaging reported improved laxity and clarity, and fewer fine lines.
- A 12-week eye-cream study in 41 women reported better results than both placebo and a vitamin K cream.
- A 12-week twice-daily facial cream study in 67 women aged 50–59 reported improvements in firmness, wrinkles and mottled pigmentation, plus increased keratinocyte proliferation on biopsy.
That sounds strong, so here is the honest caveat. Several of these were conference abstracts or book chapters rather than full peer-reviewed trials, and sample-size details are sometimes missing. A small randomized study after CO2 laser resurfacing (13 patients completed it) found no objective difference in redness, wrinkles or skin quality with GHK-Cu products. Patients in the GHK-Cu group did report higher satisfaction.2 On the safety side, the Cosmetic Ingredient Review panel concluded in 2018 that tripeptide-1 and its metal salts (the group that includes copper tripeptide-1) are safe as used in cosmetics, at typical concentrations below 10 ppm.5
So “GHK-Cu or BPC-157 for skin?” has a clear answer on the evidence. Only GHK-Cu has human skin data, and those data come from topical products, not research vials.
Hair: weaker than social media suggests
Copper peptides are often sold as hair-growth ingredients. The study most often cited, Pyo and colleagues in 2007, used AHK-Cu (a sister copper peptide), not GHK-Cu. It found that AHK-Cu stimulated the elongation of human hair follicles in culture and the proliferation of dermal papilla cells.6 That is a lab-dish result. Pickart’s 2015 skin review does not describe a human GHK-Cu hair trial.1 We dig into this in copper peptides and hair research.
Wounds: the GHK-Cu gel that didn’t make it
This is the part most vendors leave out. In the early 1990s, ProCyte developed Iamin Gel, a GHK-copper complex, for diabetic foot ulcers. A randomized, evaluator-blinded, placebo-controlled study reported median plantar ulcer closure of 98.5% with the gel versus 60.8% with vehicle, and fewer infections.3 But the larger pivotal Phase III programme, 511 patients at 30 centres, found the gel no better than placebo.4 That is a useful reminder that good small-trial results often shrink in bigger studies.
BPC-157’s wound literature is almost all rodent work, including topical application in rat skin models.7
Tendon and ligament: BPC-157’s strongest preclinical area
In a 2003 rat study, daily intraperitoneal BPC-157 after Achilles tendon transection improved biomechanical strength, functional scores and collagen organization compared with saline. In tendon cells in culture, it countered a growth-inhibiting aldehyde.9 Similar positive results appear in rat ligament and muscle models.8 A 2025 systematic review in HSS Journal screened 544 articles and included 36 studies. Of those, 35 were preclinical and only one was clinical. The review rated the evidence as low level and concluded that in-human safety “remains unknown.”10 For the bigger healing-peptide picture, see BPC-157 vs TB-500.
Gut: where BPC-157 began
Given its gastric origin, it’s no surprise that the largest block of BPC-157 papers covers stomach lesions, colitis, fistulas and short-bowel models in rats. A peptide code-named PL 14736 (the same molecule) went into early ulcerative-colitis trials in the early 2000s, but a review describes those reports as “limited and not overly informative.”8 GHK-Cu has no comparable gut programme.
What human data actually exist
This is where the two peptides differ most.
GHK-Cu in humans
- Several topical cosmetic studies in women, mostly 12 weeks long (see above).1
- A small randomized post-laser study with mixed results.2
- A diabetic-ulcer gel programme: positive early results, then a failed pivotal trial.3,4
- No published human studies of injected GHK-Cu that we could find.
BPC-157 in humans
- Knee pain (2021): a retrospective report of 12 patients given intra-articular BPC-157. Most reported relief, but there was no control group and no standardized scoring tool.11,7
- Interstitial cystitis (2024): a pilot in 12 women given BPC-157 into the bladder wall during cystoscopy. Ten reported complete symptom resolution. There was no control group, and outcomes were self-reported.12
- IV safety pilot (2025): two healthy adults received IV infusions of up to 20 mg. The authors reported no measurable changes in heart, liver, kidney or thyroid markers or blood glucose, and no side effects.13 Two people cannot establish safety.
- A Phase I trial in 42 healthy volunteers was registered in 2015 (NCT02637284), but its results were never submitted.7
Put simply: GHK-Cu has modest, imperfect human data for one use (topical skin). BPC-157 has human anecdotes dressed up as studies. Both deserve far more rigorous trials. For what has been reported about tolerability, see BPC-157 side effects and GHK-Cu side effects.
Safety and legal status in Canada
Health Canada’s August 1, 2025 advisory states that “injectable peptides are regulated as prescription drugs in Canada” and that selling unauthorized drugs is illegal. BPC-157 and GHK-Cu are both on its list of seized products.14 Topical skincare containing copper tripeptide-1 is a different regulatory category from a vial of research peptide. If you are thinking about any peptide for a health reason, talk to your doctor or pharmacist.
- GHK-Cu, topical: considered safe in cosmetics at typical concentrations.5
- GHK-Cu, injected: no human safety data. In the US, injectable GHK-Cu came off the FDA’s compounding “Category 2” list in April 2026 after its nominations were withdrawn, which does not mean it was approved. An FDA advisory committee is due to review it before the end of February 2027.15
- BPC-157: no acute toxicity reported in animal studies, but human safety is unknown.10 In July 2026 an FDA advisory committee voted 8–6 (one abstention) to recommend adding BPC-157 to the US compounding list for ulcerative colitis. That is a step toward compounding access, not an approval, and it has no effect in Canada.15 It is also on WADA’s prohibited list (class S0).10
Why they show up together (GLOW and KLOW)
Search “GHK-Cu and BPC-157 together” and you will land on blends. The logic is easy to follow. The two peptides touch different parts of the same repair story:
- GHK-Cu: matrix and collagen remodelling, copper delivery.
- BPC-157: blood-vessel formation and cell migration.
- TB-500 (often added): actin-related cell migration research.
That is the thinking behind GLOW (GHK-Cu + BPC-157 + TB-500) and KLOW (the same three plus KPV, studied for inflammatory signalling). We compare them in Wolverine vs GLOW vs KLOW.
Here’s the honest part: the case for combining them is a rationale, not evidence. We are not aware of any peer-reviewed study that tests GHK-Cu and BPC-157 together as a combination. A blend also makes it harder to tell which component caused an effect in an experiment. Some research groups prefer single-compound vials for exactly that reason.
GHK-Cu vs BPC-157 myths
“Myth: They do the same thing, so pick the cheaper one.”
They have different structures, different proposed mechanisms and different evidence bases. GHK-Cu is a skin and matrix research peptide with human topical data. BPC-157 is a tendon and gut research peptide with mostly rodent data. Choosing between them depends entirely on the research question.
“Myth: GHK-Cu is proven to regrow hair.”
The best-known copper-peptide follicle study used AHK-Cu in cultured follicles.6 There is no large controlled human GHK-Cu hair trial.
“Myth: BPC-157 has been proven in human trials.”
As of 2026, there are no published randomized controlled trials. The human record is three small uncontrolled reports and an unpublished Phase I.10,7,12,13
“Myth: GHK-Cu changes 4,000 genes, so it reverses aging.”
The gene numbers come from cell-line expression databases.1 Gene-expression shifts in a dish are a starting point for research. They don’t show that a cream or vial reverses aging in a person.
“Myth: Copper peptides worked for wounds, so they’re proven healers.”
The best-funded attempt, Iamin Gel for diabetic ulcers, failed its pivotal trial against placebo.4
“Myth: Taking them together is synergistic.”
Possibly, in theory. But synergy is a claim that needs a combination study, and we couldn’t find one.
For researchers
If your work involves matrix remodelling, copper biology or skin-cell models, GHK-Cu is the more relevant compound. If you are working on angiogenesis, tendon-fibroblast or gut-epithelium models, BPC-157 has the deeper preclinical literature to build on.
TrueLabs supplies GHK-Cu from $49 and BPC-157 from $22. For multi-compound work, we also carry GLOW70 (GHK-Cu, BPC-157 and TB-500) from $130 and KLOW80 (the same three plus KPV) from $150. All are sold in CAD, for in vitro and laboratory research only. Before you order, see How to read a peptide COA and browse the COA library. For a blend, check that the COA confirms the identity of each component.
FAQ
Tap a question to reveal the answer.
What is the main difference between GHK-Cu and BPC-157?
GHK-Cu is a three-amino-acid peptide bound to copper that occurs naturally in human blood and is studied mainly for collagen, skin remodelling and gene expression. BPC-157 is a synthetic 15-amino-acid peptide based on a gastric juice protein, studied mainly for blood-vessel growth and tendon, ligament and gut repair in rodents. Their structures, mechanisms and evidence bases are different.
Is GHK-Cu or BPC-157 better for skin?
On the evidence, GHK-Cu. It has several topical cosmetic studies in people and a 2018 safety assessment for cosmetic use, although many of those studies are small or published only as abstracts. BPC-157 has no published human skin studies, only rodent wound models.
Can GHK-Cu and BPC-157 be used together?
They are combined in research blends such as GLOW and KLOW because they touch different parts of tissue repair. However, we are not aware of any peer-reviewed study testing the two together, so any synergy is theoretical. Neither is approved for human use in Canada, and medical questions belong with your doctor.
Has BPC-157 been tested in humans?
Only in very small, uncontrolled reports: a 12-patient retrospective knee report, a 12-woman bladder pilot and a two-person IV safety pilot. A 42-volunteer Phase I trial was registered in 2015, but its results were never submitted. A 2025 systematic review concluded that human safety remains unknown.
Is there human evidence for GHK-Cu?
Yes, mostly for topical skin use. Twelve-week cream studies in women reported improvements in wrinkles, firmness and skin density, but a small randomized post-laser study found no objective benefit. A GHK-copper wound gel showed early promise for diabetic ulcers, then failed its larger pivotal trial.
Why is GHK-Cu blue and BPC-157 white?
GHK-Cu contains a copper(II) ion, which gives the complex its blue colour. BPC-157 has no metal, so the lyophilized powder is white. Colour alone does not confirm identity or purity; only a proper certificate of analysis can do that.
Is GHK-Cu the same as copper tripeptide-1 in skincare?
Copper tripeptide-1 is the cosmetic ingredient name for the copper complex of the GHK tripeptide. Cosmetic products use it at low concentrations in creams and serums. That is a different product category from a research-grade vial.
Are GHK-Cu and BPC-157 legal in Canada?
Health Canada says injectable peptides are regulated as prescription drugs, and both compounds appear on its August 2025 list of seized unauthorized products. We are not aware of either being authorized as a drug in Canada. Research suppliers sell them for laboratory use only.
Does BPC-157 cause cancer?
There is no human evidence that it does, but there is also no long-term human safety data. Because BPC-157 promotes blood-vessel formation in animal studies, researchers have raised a theoretical concern about tumour growth. That question has not been answered.
Which has more research overall?
BPC-157 has more preclinical papers, mostly in rats and largely from one research group. GHK-Cu has a longer history, going back to 1973, plus some human topical data. More papers does not mean better evidence; study type and independent replication matter more.
Related reading
- Wolverine vs GLOW vs KLOW: peptide blends compared
- What is BPC-157?
- BPC-157 oral vs injectable: what the studies used
- Copper peptides and hair research
- GHK-Cu side effects
- BPC-157 vs TB-500
References
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4). PubMed
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994. DOI
- The Pharma Letter. ProCyte’s lead product no better than placebo (Iamin Gel Phase III, 511 patients). The Pharma Letter
- Johnson W, Bergfeld WF, Belsito DV, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Int J Toxicol. 2018;37(3 suppl):90S–102S. DOI
- Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834–839. DOI
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PubMed
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PubMed
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PubMed
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. PubMed
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8–13. PubMed
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. UroToday abstract
- Lee E, Burgess A. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–24. PubMed
- Health Canada. Advisory on unauthorized injectable peptide drugs seized and sold in Canada (RA-77807). Recalls and safety alerts, August 1, 2025. Health Canada
- McDermott Will & Emery. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. July 27, 2026. McDermott
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.